Growth hormone treatment in adults with growth hormone deficiency: The transition

Journal of Endocrinological Investigation

Volumn 34, Issue 2, 2011, Pages 150-154

  Molitch, M E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Growth bone; Growth hormone; Hypopituitarism; Short stature; Transition

Indexed keywords

ARGININE GROWTH HORMONE RELEASING HORMONE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; INSULIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BONE DENSITY; BONE MASS; CHILD DEVELOPMENT; GROWTH HORMONE DEFICIENCY; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE METABOLISM; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TOLERANCE TEST; PHASE TRANSITION; PUBERTY; QUALITY OF LIFE; SHORT SURVEY;

EID: 79956344044     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/bf03347046     Document Type: Short Survey

References (73)

1. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M; European Society of Paediatric Endocrinology. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005, 152: 165-70.
2. Radovick S, DiVall S. Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab 2007, 92: 1195-200. (Pubitemid 46556384)
3. Müller EE. Clinical implications of growth hormone feedback mechanisms. Horm Res 1990, 33 (Suppl 4): 90-6. (Pubitemid 20261761)
4. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society's Clinical Guidelines Subcommittee, Stephens PA. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006, 91: 1621-34.
5. Alatzoglou KS, Dattani MT. Genetic forms of hypopituitarism and their manifestation in the neonatal period. Early Hum Dev 2009, 85: 705-12.
6. Cohen LE, Radovick S. Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 2002, 23: 431-42. (Pubitemid 34925640)
7. Cogan JD, Phillips JA III. GH1 gene deletions and IGHD type 1A. Pediatr Endocrinol Rev 2006, 3 (Suppl 3): 480-8. (Pubitemid 44745410)
8. Alatzoglou KS, Turton JP, Kelberman D, et al. Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J Clin Endocrinol Metab 2009, 94: 3191-9.
9. Mantovani G, Maghnie M, Weber G, et al. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type 1a: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab 2003, 88: 4070-4. (Pubitemid 37153698)
10. Pantel J, Legendre M, Cabrol S, et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 2006, 116: 760-8. (Pubitemid 43326885)
11. Leger J, Danner S, Simon D, Garel C, Czemichow P. Do all patients with childhood-onset growth hormone deficiency (GHD) and ectopic neurohypophysis have persistent GHD in adulthood? J Clin Endocrinol Metab 2005, 90: 650-6.
12. Maghnie M, Salati B, Bianchi S, et al. Relationship between the morphological evaluation of the pituitary and the growth hormone (GH) response to GH-releasing hormone Plus arginine in children and adults with congenital hypopituitarism. J Clin Endocrinol Metab 2001, 86: 1574-9. (Pubitemid 32374906)
13. Mulder RL, Kremer LC, van Santen HM, et al. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev 2009, 35: 616-32.
14. Gleeson HK, Gattamaneni HR, Smethurst L, Brennan BM, Shalet SM. Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy. J Clin Endocrinol Metab 2004, 89: 662-6. (Pubitemid 38269874)
15. Cacciari E, Tassoni P, Parisi G, et al. Pitfalls in diagnosing impaired growth hormone (GH) secretion: retesting after replacement therapy of 63 patients defined as GH deficient. J Clin Endocrinol Metab 1992, 74: 1284-9.
16. Clayton PE, Price DA, Shalet SM. Growth hormone state after completion of treatment with growth hormone. Arch Dis Child 1987, 62: 222-6. (Pubitemid 17056623)
17. Longobardi S, Merola B, Pivonello R, Di Rella F, Di Somma C, Colao A, et al. Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. J Clin Endocrinol Metab 1996, 81: 1244-7. (Pubitemid 26083999)
18. Nicolson A, Toogood AA, Rahim A, Shalet SM. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood [see comment]. Clin Endocrinol 1996, 44: 311-6. (Pubitemid 26063410)
19. Tauber M, Moulin P, Pienkowski C, Jouret B, Rochiccioli P. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 1997, 82: 352-6. (Pubitemid 27068591)
20. Wacharasindhu S, Cotterill AM, Camacho-Hubner C, Besser GM, Savage MO. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin Endocrinol 1996, 45: 553-6. (Pubitemid 26411355)
21. Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002, 87: 2067-79. (Pubitemid 34521490)
22. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab 2003, 88: 95-102. (Pubitemid 36115149)
23. Yuen KCJ, Biller BMK, Molitch ME, Cook DM. Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab 2009, 94: 2702-7.
24. Corneli G, Di Somma C, Prodam F, et al. Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol 2007, 157: 701-8.
25. Maghnie M, Aimaretti G, Bellone S, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol 2005, 152: 589-96. (Pubitemid 40575804)
26. Secco A, di Iorgi N, Napoli F, et al. Reassessment of the growth hormone status in young adults with childhood-onset growth hormone deficiency: reappraisal of insulin tolerance testing. J Clin Endocrinol Metab 2009, 94: 4195-204.
27. Corneli G, Di Somma C, Baldelli R, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 2005, 153: 257-64. (Pubitemid 41174451)
28. Colao A, Di Somma C, Savastano S, et al. A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J Clin Endocrinol Metab 2009, 94: 4414-22.
29. Qu XD, Gaw Gonzalo IT, Al Sayed MY, et al. Influence of body mass index and gender on growth hormone (GH) responses to GH-releasing hormone plus arginine and insulin tolerance tests. J Clin Endocrinol Metab 2005, 90: 1563-9. (Pubitemid 40464019)
30. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ; HyposCCS Advisory Board; U.S. HypoCCS Study Group. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002, 87: 477-85.
31. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL, Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1999, 84: 2013-9. (Pubitemid 30647027)
32. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KK. Diagnosis of growth-hormone deficiency in adults. Lancet 1994, 343: 1064-8.
33. Brabant G, Krogh Rasmussen A, Biller BM, et al. Clinical implications of residual growth hormone (GH) response to provocative testing in adults with severe GH deficiency. J Clin Endocrinol Metab 2007, 92: 2604-9. (Pubitemid 47037364)
34. Toogood AA, Beardwell CG, Shalet SM. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin Endocrinol 1994, 41: 511-6. (Pubitemid 24301285)
35. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009, 30: 152-77.
36. Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab 2008, 93: 4413-7. (Pubitemid 352789540)
37. Lissett CA, Murray RD, Shalet SM. Timing of onset of growth hormone deficiency is a major influence on insulin-like growth factor I status in adult life. Clin Endocrinol 2002, 57: 35-40. (Pubitemid 34785881)
38. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996, 125: 883-90.
39. Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 2000, 85: 970-6. (Pubitemid 32269335)
40. Shalet SM, Shavrikova E, Cromer M, et al. Effect of growth hormone (GH) treatment on bone in postpuberal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003, 88: 4124-9. (Pubitemid 37158031)
41. Johannsson G, Rosén T, Bosaeus I, Sjöström L, Bengtsson BA. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996, 81: 2865-73. (Pubitemid 26323877)
42. Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997, 82: 82-8. (Pubitemid 27021275)
43. Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 2004, 89: 1684-93. (Pubitemid 38514701)
44. Holmes SJ, Shalet SM. Factors influencing the desire for long-term growth hormone replacement in adults. Clin Endocrinol 1995, 43: 151-7.
45. Koltowska-Haggstrom M, Mattsson AF, Shalet SM. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol 2009, 161 (Suppl 1): S51-64.
46. Baum HB, Katznelson L, Sherman JC, et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998, 83: 3184-9. (Pubitemid 28500954)
47. Murray RD, Skillicorn CJ, Howell SJ, et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol (Oxf) 1999, 51: 565-73.
48. Teegarden D, Proulx WR, Martin BR, et al. Peak bone mass in young women. J Bone Miner Res 1995, 10: 711-5.
49. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J Pediatr Endocrinol Metab 2003, 16 (Suppl 2): 327-35. (Pubitemid 37264914)
50. Baroncelli Gl, Bertelloni S, Sodini F, Saggese G. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol 2004, 60: 175-84. (Pubitemid 38200898)
51. Drake WM, Carroll PV, Maher KT, et al. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 2003, 88: 1658-63. (Pubitemid 36623384)
52. Mukherjee A, Attanasio AF, Shalet SM. Skeletal requirements for optimal growth hormone replacement in the transitional years. Growth Horm IGF Res 2003, 13 (Suppl A): S130-5.
53. Hyer SL, Rodin DA, Tobias JH, Leiper A, Nussey SS. Growth hormone deficiency during puberty reduces adult bone mineral density. Arch Dis Child 1992, 67: 1472-4. (Pubitemid 23008273)
54. Underwood LE, Attie KM, Baptista J; Genentech Collaborative Study Group. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003, 88: 5273-80. (Pubitemid 37452727)
55. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 2002, 17: 1081-94. (Pubitemid 34535147)
56. Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B; Transition Study Group. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005, 90: 3946-55. (Pubitemid 41065023)
57. Boot AM, van der Sluis IM, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency. Horm Res 2009, 71: 364-71.
58. Conway GS, Szarras-Czapnik M, Racz K, et al; 1369 GHD to GHDA Transition Study Group. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 2009, 160: 899-907.
59. Nguyen VT, Misra M. Transitioning of children with GH deficiency to adult dosing: changes in body composition. Pituitary 2009, 12: 125-35.
60. Attanasio AF, Shavrikova E, Blum WF, et al; Hypopituitary Developmental Outcome Study Group. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab 2004, 89: 4857-62. (Pubitemid 39403060)
61. Carroll PV, Drake WM, Maher KT, et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 2004, 89: 3890-5. (Pubitemid 39071490)
62. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010, 95: 167-77.
63. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002, 360: 273-7.
64. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006, 91: 3494-8. (Pubitemid 44402126)
65. Darendeliler F, Karagiannis G, Wilton P, Ranke MB, Albertsson-Wikland K, Anthony Price D, on behalf of the KIGS International B. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr 2006, 95: 1284-90.
66. Arnold JR, Arnold DF, Marland A, Karavitaki N, Wass JA. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol 2009, 70: 435-8.
67. Buchfelder M, Kann PH, Wüster C, et al. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur J Endocrinol 2007, 157: 149-56. (Pubitemid 47233118)
68. Chung TT, Drake WM, Evanson J, et al. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin Endocrinol (Oxf) 2005, 63: 274-9. (Pubitemid 41233444)
69. Frajese G, Drake WM, Loureiro RA, et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 2001, 86: 5172-5.
70. Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, Russell-Jones DL. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol 2002, 146: 807-11. (Pubitemid 34705073)
71. Jostel A, Mukherjee A, Hulse PA, Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf) 2005, 62: 698-705. (Pubitemid 40825940)
72. Karavitaki N, Warner JT, Marland A, et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 2006, 64: 556-60.
73. Olsson DS, Buchfelder M, Schlaffer S, et al. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur J Endocrinol 2009, 161: 663-9.